Find Reports

Select Report Type

Learn More about Reports

Reimbursement Review

Export to CSV
Displaying 26 - 50 of 1258
Please scroll or swipe to the right to view the full content.
Brand Name Generic Name Files Therapeutic Area Recommendation Type Status Submission Date Recommendation Date Project Number
Keytruda pembrolizumab
Recommendation and Reason Clinical and Pharmacoeconomic Combined ReportFeedback on Draft RecommendationPatient and Clinician Group Input
 Gastric or gastroesophageal junction (GEJ) adenocarcinoma Reimburse with clinical criteria and/or conditions Complete PC0356-000
Verzenio abemaciclib
Recommendation and Reason Patient and Clinician Group input
 Adjuvant treatment of HR-positive, HER2-negative early breast cancer Reimburse with clinical criteria and/or conditions Active PC0345-000
Tagrisso osimertinib
Recommendation and Reason Patient and Clinician Group InputClinical and Pharmacoeconomic Combined ReportFeedback on Draft Recommendation
 Non-small cell lung cancer Reimburse with clinical criteria and/or conditions Complete PC0336-000
Olumiant baricitinib
Recommendation and ReasonsPatient and Clinician Group input
 Alopecia areata, severe Reimburse with clinical criteria and/or conditions Active SR0843-000
Cosentyx secukinumab
Recommendation and ReasonsPatient and Clinician Group inputClinical and Pharmacoeconomic Combined ReportFeedback on Draft Recommendation
 Hidradenitis suppurativa Reimburse with clinical criteria and/or conditions Complete SR0781-000
Truqap capivasertib
Recommendation and ReasonsClinical and Pharmacoeconomic Combined ReportFeedback on Draft RecommendationPatient and Clinician Group Input
 HR-positive, HER2-negative locally advanced or metastatic breast cancer Reimburse with clinical criteria and/or conditions Complete PC0341-000
Adcetris Brentuximab vedotin
Recommendation and ReasonsClinical and Pharmacoeconomic Combined ReportFeedback on Draft RecommendationPatient and Clinician Group Input
 Hodgkin lymphoma Reimburse with clinical criteria and/or conditions Complete PC0371-000
Veklury remdesivir
Recommendation and Reason Clinical and Pharmacoeconomic Combined ReportFeedback on Draft RecommendationPatient and Clinician Group Input
 COVID-19 in hospitalized patients Reimburse with clinical criteria and/or conditions Complete SR0833-000
Veklury remdesivir
Recommendation and Reason Clinical and Pharmacoeconomic Combined ReportPatient and Clinician Group InputStakeholder feedback on Draft Recommendation
 COVID-19 in non-hospitalized patients Reimburse with clinical criteria and/or conditions Complete SR0834-000
Leqvio inclisiran
Recommendation and ReasonsClinical and Pharmacoeconomic Combined ReportFeedback on Draft RecommendationPatient and Clinician Group Input
 Primary hypercholesterolemia Reimburse with clinical criteria and/or conditions Complete SR0791-000
Vraylar cariprazine
Recommendation and Reason Clinical and Pharmacoeconomic Combined ReportFeedback on Draft RecommendationPatient and Clinician Group Input
 Schizophrenia Reimburse with clinical criteria and/or conditions Complete SR0827-000
Apretude cabotegravir
Recommendation and Reason Patient and Clinician Group InputClinical and Pharmacoeconomic Combined ReportStakeholder feedback on Draft Recommendation
 HIV-1 infection, pre-exposure prophylaxis Reimburse with clinical criteria and/or conditions Complete SR0825-000
Velsipity etrasimod
Recommendation and Reason Patient and Clinician Group InputClinical and Pharmacoeconomic Combined ReportStakeholder feedback on Draft Recommendation
 Ulcerative colitis Reimburse with clinical criteria and/or conditions Complete SR0795-000
Repatha evolocumab
Recommendation and Reason Clinical and Pharmacoeconomic Combined ReportFeedback on Draft RecommendationPatient and Clinician Group Input
 Primary hyperlipidemia Reimburse with clinical criteria and/or conditions Complete SR0821-000
N/A Pembrolizumab
Recommendation and Reason Responses to Questions From the Drug ProgramsClinical and Pharmacoeconomic Combined ReportStakeholder Input
 Melanoma (Skin) Reimburse with clinical criteria and/or conditions Complete PX0346-000
N/A Nivolumab and Ipilimumab
Recommendation and ReasonsResponses to Questions From the Drug ProgramsClinical and Pharmacoeconomic combined ReportStakeholder Input
 Melanoma (Skin) Reimburse with clinical criteria and/or conditions Complete PX0347-000
N/A Nab-paclitaxel
Recommendation and reasonsResponses to Questions From the Drug ProgramsClinical and Pharmacoeconomic Combined ReportPatient and Clinician Group Input
 Solid tumours Reimburse with clinical criteria and/or conditions Complete PX0348-000
Orgovyx relugolix
Recommendation and Reason Clinical and Pharmacoeconomic Combined ReportStakeholder feedback on Draft RecommendationPatient and Clinician Group input
 Advanced prostate cancer Reimburse with clinical criteria and/or conditions Complete PC0342-000
Qulipta atogepant
Recommendation and Reason Clinical and Pharmacoeconomic Combined ReportFeedback on Draft RecommendationPatient and Clinician Group input
 Migraine, prevention Reimburse with clinical criteria and/or conditions Complete SR0817-000
Keytruda pembrolizumab
Recommendation and Reason Clinical and Pharmacoeconomic Combined ReportFeedback on Draft RecommendationPatient and Clinician Group input
 Biliary tract carcinoma Reimburse with clinical criteria and/or conditions Complete PC0344-000
Keytruda pembrolizumab
Recommendation and Reason Patient and Clinician Group inputClinical and Pharmacoeconomic Combined ReportStakeholder feedback on Draft Recommendation
 Gastric or gastroesophageal junction adenocarcinoma Reimburse with clinical criteria and/or conditions Complete PC0343-000
Eylea HD aflibercept 8mg/0.07mL
Recommendation and ReasonsPatient and Clinician Group inputClinical and Pharmacoeconomic Combined ReportStakeholder feedback on Draft Recommendation
 macular degeneration, age related Reimburse with clinical criteria and/or conditions Complete SR0812-000
Eylea HD aflibercept 8mg/0.07mL
Recommendation and ReasonsClinical, Pharmacoeconomic and Ethics combined ReportStakeholder feedback on Draft Recommendation
 diabetic macular edema Reimburse with clinical criteria and/or conditions Complete SR0813-000
Elrexfio elranatamab
Recommendation and Reason Patient and Clinician Group inputClinical and Pharmacoeconomic Combined ReportStakeholder feedback on Draft Recommendation
 Relapsed or refractory multiple myeloma Reimburse with clinical criteria and/or conditions Complete PC0315-000
Epkinly epcoritamab
Recommendation and ReasonsPatient and Clinician Group inputClinical and Pharmacoeconomic Combined ReportFeedback on Draft Recommendation
 Relapsed or refractory diffuse large B-cell lymphoma Time-limited reimbursement recommendation Complete PC0334-000

Health Technology Review

Last Updated
Export to CSV
Displaying 26 - 50 of 589
Please scroll or swipe to the right to view the full content.
Title Description Files Last Updated Project Sub Line Status Project Number
GLP-1 Receptor Agonists and Self-Harm
Observational Study Active OS0009-000
Early Biologic Treatment for Inflammatory Bowel Disease
Early Biologic Treatment for Inflammatory Bowel Disease
Rapid Review Completed RC1552-000
Gabapentin for Seizures
Gabapentin for Seizures
Rapid Review Completed RC1557-000
The Utilization of PCSK9 Inhibitors in Familial Hypercholesterolemia
Technology Review Active HC0094-000
Airway Management in Out-of-Hospital Emergencies
Airway Management in Out-of-Hospital Emergencies
Rapid Review Completed RC1555-000
BRAF and MEK Inhibitors for Active or Symptomatic Melanoma Brain Metastasis
BRAF and MEK Inhibitors for Active or Symptomatic Melanoma Brain Metastasis
Rapid Review Completed RC1549-000
Re-treatment With Immune Checkpoint Inhibitors: Utilization Analysis
Technology Review In Progress HC0093-000
The Effectiveness of PCSK9 Inhibitors in Familial Hypercholesterolemia
Observational Study Active OS0011-000
The Cost-Effectiveness and Budget Impact of Remdesivir for Outpatient Treatment of COVID-19
Technology Review In Progress HE0049-000
The Cost-Effectiveness and Budget Impact of Tocilizumab for COVID-19
Technology Review Active HE0051-000
The Cost-Effectiveness and Budget Impact of Remdesivir for Inpatient Treatment of COVID-19
Technology Review Active HE0050-000
Bilateral Opportunistic Salpingectomy to Reduce the Incidence of Ovarian Cancer
Bilateral Opportunistic Salpingectomy to Reduce the Incidence of Ovarian Cancer
 Summary with Critical Appraisal Completed RC1550-000
Lenvatinib for the Treatment of Hepatocellular Carcinoma After Liver Transplant
Lenvatinib for the Treatment of Hepatocellular Carcinoma After Liver Transplant
Rapid Review Completed RC1553-000
Switching Calcitonin Gene–Related Peptide Inhibitors for Migraine Prophylaxis
Switching Calcitonin Gene–Related Peptide Inhibitors for Migraine Prophylaxis
Peer-reviewed Summary with Critical Appraisal Completed RD0071-000
Cost-Effectiveness of Conjugate Pneumococcal Vaccines in At-Risk Adults Aged 18 to 64 Years
Cost-Effectiveness of Conjugate Pneumococcal Vaccines in At-Risk Adults Aged 18…
 Technology Review Completed HE0054-000
Short-Cycle Autoclave Sterilization of Instruments in Same-Day Ophthalmic Surgeries
Short-Cycle Autoclave Sterilization of Instruments in Same-Day Ophthalmic Surgeries
Rapid Review Completed RC1547-000
Continuously Diffused Therapy for Wound Healing To inform decisions about continuously diffused oxygen (CDO) therapy for wound healing, we identified and summarized literature comparing the clinical effectiveness and cost-effectiveness of CDO therapy versus conventional wound care.
Continuously Diffused Therapy for Wound Healing
Rapid Review Completed RC1548-000
The Cost-Effectiveness and Budget Impact of Nirmatrelvir-Ritonavir for COVID-19
Technology Review Active HE0048-000
Review of Guidelines on Second-Line Therapy for Patients With Relapsing-Remitting Multiple Sclerosis: A 2024 Update
Review of Guidelines on Second-Line Therapy for Patients With Relapsing-Remitting Multiple Sclerosis: A 2024 Update
Rapid Review Completed RC1541-000
Thrombopoietin Receptor Agonists as Second-Line Treatment in Children With Ongoing Immune Thrombocytopenia
Thrombopoietin Receptor Agonists as Second-Line Treatment in Children With Ongo…Protocol List of included studies
 Technology Review Completed HC0033-000
Methoxyflurane Inhalation as an Analgesic for Minor Gynecological, Ambulatory, or Emergency Procedures
Methoxyflurane Inhalation as an Analgesic for Minor Gynecological, Ambulatory, or Emergency Procedures
Rapid Review Completed RC1545-000
Retesting Intervals for Tryptase
Retesting Intervals for Tryptase
Rapid Review Completed RC1546-000
Drug Shortages and Patient Harms The objective of our report is to summarize the evidence on patient outcomes associated with supply chain disruptions of pharmaceuticals and vaccines.
Drug Shortages and Patient Harms
 Technology Review Completed HC0072-000
Safety of Ozempic for Type II Diabetes
Final ReportSummary Report
 Observational Study Completed OS0005-000
An Inventory of Rare Disease Registries in the Canadian Landscape
An Inventory Report of Rare Disease Registries in the Canadian Landscape
 Environmental Scan Completed CP0033-000

Horizon Scan

Last Updated
Export to CSV
Displaying 26 - 50 of 111
Please scroll or swipe to the right to view the full content.
Title Description Files Last Updated Project Sub Line Status Project Number
An Overview of Emerging Trends and Technologies in Ulcerative Colitis
An Overview of Emerging Trends and Technologies in Ulcerative Colitis
 Emerging Health Technologies Complete EH0117-000
Facial Analysis Technology for Pain Detection
Facial Analysis Technology for Pain Detection
Health Technology Update Completed EN0047-000
An Overview of Clinical Applications of Virtual and Augmented Reality
An Overview of Clinical Applications of Virtual and Augmented Reality
Emerging Health Technologies Completed EH0111-000
Xylazine Test Strips for Drug Checking
Xylazine Test Strips for Drug Checking
 Health Technology Update Completed EN0049-000
Hearing Aids and Dementia
Hearing Aids and Dementia
Emerging Health Technologies Completed EH0120-000
Rapid HIV Self-Testing
Rapid HIV Self-Testing
 Emerging Health Technologies Completed EH0118-000
Hybrid Operating Rooms Suites
Hybrid Operating Rooms Suites
Emerging Health Technologies Completed EH0121-000
An Overview of Pharmacogenomic Testing for Psychiatric Disorders
An Overview of Pharmacogenomic Testing for Psychiatric Disorders
Emerging Health Technologies Completed EH0115-000
Cognitive Health Assessment Management Platform
Cognitive Health Assessment Management Platform
Health Technology Update Completed EN0046-000
Reducing the Environmental Impact of Clinical Care
Reducing the Environmental Impact of Clinical Care
Completed EH0112-000
Laser Treatment for Lower Back Pain
Laser Treatment for Lower Back Pain
Health Technology Update Completed EN0044-000
Point-of-Care Tests for Pancreatitis
Point-of-Care Tests for Pancreatitis
 Health Technology Update Completed EN0045-000
Wastewater Surveillance for Communicable Disease
Wastewater Surveillance for Communicable Disease
 Emerging Health Technologies Completed EH0114-000
Robotic Surgical Systems for Orthopedics
Robotic Surgical Systems for Orthopedics
 Emerging Health Technologies Completed EH0108-000
Rapid Syphilis Testing
Rapid Syphilis Testing
 Health Technology Update Completed EN0043-000
Vagus Nerve Stimulation for the Treatment of Post–COVID-19 Condition
Vagus Nerve Stimulation for the Treatment of Post–COVID-19 Condition
 Health Technology Update Active EN0040-000
An Overview of Comprehensive Genomic Profiling Technologies to Inform Cancer Care
An Overview of Comprehensive Genomic Profiling Technologies to Inform Cancer Ca…
 Emerging Health Technologies Completed EH0106-000
Understanding the Portrait of Dementia Care in Canada: Our Panel of Experts
Understanding the Portrait of Dementia Care in Canada: Our Panel of Experts
 Emerging Health Technologies Completed EH0110-000
Autologous Hematopoietic Stem Cell Transplant for People With Multiple Sclerosis
HTERP Guidance Statement – AHSCT for treatment of Multiple SclerosisHorizon Scan - Bulletin
 Optimal Use Complete EH0093 / OP0551
Trace Amine-Associated Receptor 1 Agonists for Schizophrenia
Trace Amine-Associated Receptor 1 Agonists for Schizophrenia
 Emerging Health Technologies Completed EH0105-000
Self-Collection of Nose and Throat Swab Samples for SARS-CoV-2 Antigen Testing
Self-Collection of Nose and Throat Swab Samples for SARS-CoV-2 Antigen Testing
 Emerging Health Technologies Completed EH0109-000
An Overview of Continuous Learning Artificial Intelligence-Enabled Medical Devices
An Overview of Continuous Learning Artificial Intelligence-Enabled Medical Devi…
 Emerging Health Technologies Completed EH0102-000
An Overview of New and Emerging Technologies for Early Diagnosis of Alzheimer Disease
An Overview of New and Emerging Technologies for Early Diagnosis of Alzheimer D…
 Emerging Health Technologies Completed EH0103-000
Tirzepatide for Type 2 diabetes mellitus
Tirzepatide for Type 2 diabetes mellitus
Emerging Health Technologies Completed EH0104-000
Emerging Multi-Cancer Early Detection Technologies
Emerging Multi-Cancer Early Detection Technologies
 Health Technology Update Completed EN0037-000

Projects in Progress

Last Updated
Export to CSV
Displaying 26 - 40 of 40
Please scroll or swipe to the right to view the full content.
Title Description Files Last Updated Project Line Project Sub Line Project Number
Newborn screening - Drugs for Rare Diseases Strategy
Health Technology Review Technology Review HC0079-000
Methodology for Ethics Analysis in Pharmaceutical Reimbursement Reviews
Health Technology Review MG0027-000
Drug Shortages in Canada - Delphi Panel
Health Technology Review Technology Review HC0074-000
Utilization of Antidiabetic Drugs During Pregnancy
Health Technology Review Technology Review HC0083-000 — OS0007-000
Patterns in Utilization of Long-Acting Inhaled Drugs for the Treatment of Chronic Obstructive Pulmonary Disease
Health Technology Review Technology Review HC0086 -000
Calcitonin Gene-Related Peptide Inhibitors for Migraine Prophylaxis
Health Technology Review Technology Review HC0081-000
Immune checkpoint inhibitors for mutated non–small cell lung cancer
Health Technology Review Observational Study OS0008-000
Drug Shortages in Canada — Expert Panel
Health Technology Review Technology Review HC0074-000
Policies for Pediatric Medicines
Health Technology Review Environmental Scan ES0376-000
Transition from alteplase (tPA) to tenecteplase (TNK) for thrombolysis for acute ischemic stroke
Health Technology Review Policy Insight CY0015-000
RWE Learning Project Non-Oncology: Ocaliva
Health Technology Review Technology Review HC0046-000
Health Technology Assessment Recommendations and Managed Entry Agreements Related to Optimizing the Treatment for Pediatric Spinal Muscular Atrophy
Health Technology Review Environmental Scan ES0368-000
Interventions for the treatment of obstructive sleep apnea: economic update
Health Technology Review Technology Review HE0038-000
Formulary Management of Targeted Immune Modulators for Ulcerative Colitis
Health Technology Review Technology Review HD0010-000
Criteria for conducting Environmental Assessments in CADTH HTAs
Health Technology Review MG0017-000

View All Reports

Last Updated
Export to CSV
Displaying 26 - 50 of 2093
Please scroll or swipe to the right to view the full content.
Title Description Files Last Updated Project Line Project Sub Line Status Project Number
Gastric cancer
Reimbursement Review In Progress PH0080-000
Prostate cancer
Final Report
 Reimbursement Review Provisional Funding Algorithm Complete PH0057-000
bulevirtide
Reimbursement Review Pending SR0881-000
clascoterone
Draft Recommendation Patient and Clinician Group input
 Reimbursement Review Active SR0863-000
risankizumab
Recommendation and ReasonsClinical, Pharmacoeconomic, and Stakeholder Input Combined ReportStakeholder Feedback on Draft Recommendation
 Reimbursement Review Complete SR0767-000
nemolizumab
Reimbursement Review Active SR0861-000
trastuzumab deruxtecan
Patient and Clinician Group Input
 Reimbursement Review Active PC0367-000
alectinib
Recommendation and Reason Patient, Clinician and Industry Group Input
 Reimbursement Review Active PC0350-000
Anaplastic Lymphoma Kinase (ALK) -Positive Non-small Cell Lung Cancer (NSCLC)
Final Report
 Reimbursement Review Provisional Funding Algorithm Complete PH0058-000
omaveloxolone
Patient and Clinician Group input
 Reimbursement Review Active SR0864-000
pemigatinib
Patient and Clinician Group input
 Reimbursement Review Active PC0391-000
polatuzumab vedotin
Patient and Clinician Group Input
 Reimbursement Review Active PC0397-000
ferric carboxymaltose
Draft Recommendation and ReasonsPatient and Clinician Group input
 Reimbursement Review Active SR0852-000
ivosidenib
Recommendation and Reason Patient and Clinician Group InputClinical and Pharmacoeconomic Combined ReportFeedback on Draft Recommendation
 Reimbursement Review Complete PC0349-000
odevixibat
Reimbursement Review Pending SR0884-000
Virtual Mental Health Counselling
Virtual Mental Health Counselling
Health Technology Review Rapid Review Completed RC1569-000
crovalimab
Patient and Clinician Group input
 Reimbursement Review Active SR0858-000
pasireotide
Patient and Clinician Group input
 Reimbursement Review Active SR0859-000
fecal microbiota
Patient and Clinician Group Input
 Reimbursement Review Active SR0850-000
dostarlimab
Patient and Clinician Group Input
 Reimbursement Review Active PC0381-000
pembrolizumab
Draft RecommendationPatient and Clinician Group input
 Reimbursement Review Active PC0369-000
pembrolizumab
Draft RecommendationPatient and Clinician Group input
 Reimbursement Review Active PC0377-000
zolbetuximab
Draft RecommendationPatient and Clinician Group Input
 Reimbursement Review Active PC0338-000
pertuzumab
Proposed Scope
 Reimbursement Review Active PX0379-000
mirikizumab
Reimbursement Review Pending SR0880-000